|
1
|
Yamamoto T, Satoi S, Yamaki S, Hashimoto
D, Ishida M, Ikeura T, Hirooka S, Matsui Y, Boku S, Nakayama S, et
al: Intraperitoneal paclitaxel treatment for patients with
pancreatic ductal adenocarcinoma with peritoneal dissemination
provides a survival benefit. Cancers (Basel).
14(1354)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
DeWitt J, Yu M, Al-Haddad MA, Sherman S,
McHenry L and Leblanc JK: Survival in patients with pancreatic
cancer after the diagnosis of malignant ascites or liver metastases
by EUS-FNA. Gastrointest Endosc. 71:260–265. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Satoi S, Fujii T, Yanagimoto H, Motoi F,
Kurata M, Takahara N, Yamada S, Yamamoto T, Mizuma M, Honda G, et
al: Multicenter phase II study of intravenous and intraperitoneal
paclitaxel with S-1 for pancreatic ductal adenocarcinoma patients
with peritoneal metastasis. Ann Surg. 265:397–401. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Thomassen I, Lemmens VE, Nienhuijs SW,
Luyer MD, Klaver YL and de Hingh IH: Incidence, prognosis, and
possible treatment strategies of peritoneal carcinomatosis of
pancreatic origin: a population-based study. Pancreas. 42:72–75.
2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Satoi S, Yanagimoto H, Yamamoto T,
Toyokawa H, Hirooka S, Yamaki S, Opendro SS, Inoue K, Michiura T,
Ryota H, et al: A clinical role of staging laparoscopy in patients
with radiographically defined locally advanced pancreatic ductal
adenocarcinoma. World J Surg Oncol. 14(14)2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Yamada S, Fujii T, Yamamoto T, Takami H,
Yoshioka I, Yamaki S, Sonohara F, Shibuya K, Motoi F, Hirano S, et
al: Phase I/II study of adding intraperitoneal paclitaxel in
patients with pancreatic cancer and peritoneal metastasis. Br J
Surg. 107:1811–1817. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Evans DB, Rich TA, Byrd DR, Cleary KR,
Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ and Ames FC:
Preoperative chemoradiation and pancreaticoduodenectomy for
adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339.
1992.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mackay TM, van Erning FN, van der Geest
LGM, de Groot JWB, Haj Mohammad N, Lemmens VE, van Laarhoven HW,
Besselink MG and Wilmink JW: Dutch Pancreatic Cancer Group.
Association between primary origin (head, body and tail) of
metastasised pancreatic ductal adenocarcinoma and oncologic
outcome: A population-based analysis. Eur J Cancer. 106:99–105.
2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Takahara N, Isayama H, Nakai Y, Sasaki T,
Saito K, Hamada T, Mizuno S, Miyabayashi K, Mohri D, Kogure H, et
al: Pancreatic cancer with malignant ascites: Clinical features and
outcomes. Pancreas. 44:380–385. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825.
2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Ishigami H, Kitayama J, Kaisaki S,
Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H
and Nagawa H: Phase II study of weekly intravenous and
intraperitoneal paclitaxel combined with S-1 for advanced gastric
cancer with peritoneal metastasis. Ann Oncol. 21:67–70.
2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Markman M, Brady MF, Spirtos NM, Hanjani P
and Rubin SC: Phase II trial of intraperitoneal paclitaxel in
carcinoma of the ovary, tube, and peritoneum: A Gynecologic
Oncology Group Study. J Clin Oncol. 16:2620–2624. 1998.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Yamamoto T, Fujii T, Hirano S, Motoi F,
Honda G, Uemura K, Kitayama J, Unno M, Kodera Y, Yamaue H, et al:
Randomized phase III trial of intravenous and intraperitoneal
paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for
pancreatic ductal adenocarcinoma with peritoneal metastasis (SP
study). Trials. 23(119)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Yamada S, Fujii T, Yamamoto T, Takami H,
Yoshioka I, Yamaki S, Sonohara F, Shibuya K, Motoi F, Hirano S, et
al: Conversion surgery in patients with pancreatic cancer and
peritoneal metastasis. J Gastrointest Oncol. 12 (Suppl
1):S110–S117. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ishigami H, Kitayama J, Otani K, Kamei T,
Soma D, Miyato H, Yamashita H, Hidemura A, Kaisaki S and Nagawa H:
Phase I pharmacokinetic study of weekly intravenous and
intraperitoneal paclitaxel combined with S-1 for advanced gastric
cancer. Oncology. 76:311–314. 2009.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Meguro Y, Yamaguchi H, Sasanuma H,
Shimodaira K, Aoki Y, Chinen T, Morishima K, Miyato H, Miki A, Endo
K, et al: Combined intraperitoneal paclitaxel and systemic
chemotherapy for patients with massive malignant ascites secondary
to pancreatic cancer: A report of two patients. Intern Med.
63:2015–2021. 2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Nitsche U, Wenzel P, Siveke JT, Braren R,
Holzapfel K, Schlitter AM, Stöß C, Kong B, Esposito I, Erkan M, et
al: Resectability after first-line FOLFIRINOX in initially
unresectable locally advanced pancreatic cancer: A single-center
experience. Ann Surg Oncol. 22 (Suppl 3):S1212–S1220.
2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ishigami H, Fujiwara Y, Fukushima R,
Nashimoto A, Yabusaki H, Imano M, Imamoto H, Kodera Y, Uenosono Y,
Amagai K, et al: Phase Ill trial comparing intraperitoneal and
intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in
patients with gastric cancer with peritoneal metastasis: Phoenix-GC
Trial. J Clin Oncol. 36:1922–1929. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Satoi S, Yamaue H, Kato K, Takahashi S,
Hirono S, Takeda S, Eguchi H, Sho M, Wada K, Shinchi H, et al: Role
of adjuvant surgery for patients with initially unresectable
pancreatic cancer with a long-term favorable response to
non-surgical anti-cancer treatments: Results of a project study for
pancreatic surgery by the Japanese Society of
Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci.
20:590–600. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Satoi S, Yamamoto T, Yamaki S, Sakaguchi T
and Sekimoto M: Surgical indication for and desirable outcomes of
conversion surgery in patients with initially unresectable
pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 4:6–13.
2020.PubMed/NCBI View Article : Google Scholar
|
